Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human TGFBR1 Anticorps:
anti-Mouse (Murine) TGFBR1 Anticorps:
anti-Rat (Rattus) TGFBR1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal TGFBR1 Primary Antibody pour IF (p), IHC (p) - ABIN671256
Xie, Chen, Miao, Tang, Fu: Regulation of cellular behaviors of fibroblasts related to wound healing by sol-gel derived bioactive glass particles. dans Journal of biomedical materials research. Part A 2016
Show all 3 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody pour IHC (p), WB - ABIN392279
Miles, Tung, Aguiar, Kurtoglu, Sikes: Increased TGF-?1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling. dans The Prostate 2012
Show all 2 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody pour ELISA, WB - ABIN563176
Matsunobu, Torigoe, Ishikawa, de Vega, Kulkarni, Iwamoto, Yamada: Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. dans Developmental biology 2009
Human Polyclonal TGFBR1 Primary Antibody pour IF, WB - ABIN317892
Yu, Hu, Yang, Takemori, Li, Zheng, Hong, Liao, Wen: Salt-inducible kinase 1 is involved in high glucose-induced mesangial cell proliferation mediated by the ALK5 signaling pathway. dans International journal of molecular medicine 2013
Mouse (Murine) Monoclonal TGFBR1 Primary Antibody pour FACS - ABIN4896300
Bodogai, Moritoh, Lee-Chang, Hollander, Sherman-Baust, Wersto, Araki, Miyoshi, Yang, Trinchieri, Biragyn: Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. dans Cancer research 2015
DZNep induced miR (Montrer MLXIP Anticorps)-202-5p to target both TGFbeta (Montrer TGFB1 Anticorps) receptors, TGFBR1 and TGFBR2 (Montrer TGFBR2 Anticorps)...transfection of anti-miRNAs against miR (Montrer MLXIP Anticorps)-202-5p resulted in increased TGFBR1 and TGFBR2 (Montrer TGFBR2 Anticorps) protein expressions and induced EMT (Montrer ITK Anticorps) characteristics in these cells. In stellate pancreatic cells, miR (Montrer MLXIP Anticorps)-202 overexpression slowed growth as well as reduced stromal extracellular membrane matrix protein expression
Findings provide evidence that TGFBR-1 expression is regulated by SLC35F2 (Montrer SLC35F2 Anticorps) which exerts its oncogenic effect on papillary thyroid carcinoma progression through activation of TGFBR-1 and ASK-1 (Montrer MAP3K5 Anticorps).
miR (Montrer MLXIP Anticorps)-130a-3p might play a critical role in negatively regulating hepatic stellate cell activation and proliferation in the progression of nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2 (Montrer TGFBR2 Anticorps) via the TGF-beta (Montrer TGFB1 Anticorps)/SMAD (Montrer SMAD1 Anticorps) signaling pathway.
TGFbetaR1 signaling was involved in 14-3-3zeta (Montrer YWHAZ Anticorps)-mediated cell proliferation and metastasis of lung squamous cell carcinoma cells.
Mutational activation of BRAF (Montrer BRAF Anticorps) confers sensitivity to TGFBR1 inhibitors in human melanoma cells.
Loeys-Dietz syndrome patients with confirmed mutations in TGFBR1 or TGFBR2 (Montrer TGFBR2 Anticorps) had an increased prevalence of inflammatory bowel disease
ALK5 is an important mediator of HTFs fibrosis. ALK5 is a potential therapeutic target to suppress scar formation after filtration surgery.
PAR2 (Montrer F2RL1 Anticorps) is crucial for TGF-beta1 (Montrer TGFB1 Anticorps)-induced cell motility by its ability to sustain expression of ALK5. Therapeutically targeting PAR2 (Montrer F2RL1 Anticorps) may thus be a promising approach in preventing TGF-beta (Montrer TGFB1 Anticorps)-dependent driven metastatic dissemination in PDAC and possibly other stroma-rich tumour types.
results suggest a role for prostatic expression of TGF-B, IL-1a (Montrer IL1A Anticorps), TGFBRI and TGFBRII as prognostic markers for prostate cancer. The rational combination of novel agents directed toward the inactivation of TGF-B, IL-1a (Montrer IL1A Anticorps), TGFBRI and TGFBRII could disrupt complementary tumor cell proliferation pathways.
Data show that twist-related protein 1 (Twist1 (Montrer TWIST1 Anticorps)) requires TGF-beta type-I receptor (TGFBR1)-activation for activation for epithelial-mesenchymal transition (EMT (Montrer ITK Anticorps))-induction.
The results indicate that the TGFBR1 gene polymorphism (SNP64) is significantly associated with growth rates including average daily gains between birth and 56 kg, between 5.5 and 56 kg, between 35 and 56 kg.
Report temporal regulation of TGFBR1 mRNA expression in the oocyte, granulosa and theca cells of developing preovulatory follicles in the pig.
TGFbeta (Montrer TGFB1 Anticorps) is abundant in boar seminal plasma, thus TGFbeta (Montrer TGFB1 Anticorps) may be a male-female signalling agent involved in immune changes in the female reproductive tract elicited by seminal fluid.
Porcine transforming growth factor beta receptor 1 has many polymorphisms, including two nonsynonymous substitutions in exons 1 and 7 and novel alternative splicing in exon 3.
isolation and molecular characterization; the full-length TGFBR1 cDNA 1813 bp contains an open reading frame (ORF) of 1512 bp encoding a TGFBR1 protein of 503 amino acids with a calculated molecular weight of 56.4 kDa.
Results show that ALK5 and ALK1 (Montrer ACVRL1 Anticorps) play antagonistic roles in TGF-beta (Montrer TGFB1 Anticorps)-induced podosome formation in aortic endothelial cells.
This study showed that ubiquitinated ALK5 and phosphorylated heat shock protein 27 (Montrer HSP27 Anticorps) specifically accumulate in the cytoskeleton fraction, and ALK1 (Montrer ACVRL1 Anticorps) and ALK5 interact with heat shock protein 90 (Montrer HSP90 Anticorps).
GM-CSF (Montrer CSF2 Anticorps) induced airway smooth muscle cells to increase expression of transforming growth factor (TGF)-beta (Montrer TGFB1 Anticorps) receptors type I, II, and III, but had no detectable effect on the release of TGF-beta1 (Montrer TGFB1 Anticorps) by the same ASMC; corticosteroids were inhibitory
ALK5 and Smad4 (Montrer SMAD4 Anticorps) have roles in TGF-beta1 (Montrer TGFB1 Anticorps)-induced pulmonary endothelial permeability
These results indicate that high plasma cholesterol levels may contribute to the pathogenesis of certain diseases (e.g., atherosclerosis) by suppressing TGF-beta (Montrer TGFB1 Anticorps) responsiveness.
Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
ALK1 (Montrer ACVRL1 Anticorps) and ALK5 are both essential for correct regulation of VEGF (Montrer VEGFA Anticorps), and that disruption of either pathway leads to disease.
TGF-beta1 (Montrer TGFB1 Anticorps) downregulates caveolin-1 (Montrer CAV1 Anticorps) of cultured endothelial cells, involving ALK-5 receptor subtype
Taken together, these results indicate that eIF6 (Montrer EIF6 Anticorps) may be involved in external mechanical force-mediated murine dermal fibroblast function at least partly through the TGF-beta1 (Montrer TGFB1 Anticorps)/TGFBR1/TGFBR2 (Montrer TGFBR2 Anticorps) pathway.
expression induced by IL-6 (Montrer IL6 Anticorps) in keratinocytes
Loss of smooth muscle cell-Tgfbr1 triggers multiple deleterious pathways, including abnormal TGFBR2 (Montrer TGFBR2 Anticorps), ERK (Montrer EPHB2 Anticorps), and AngII/AT1R (Montrer AGTRAP Anticorps) signals that disrupt aortic wall homeostasis to cause aortic aneurysm formation
Deletion of smooth muscle cell-specific Tgfbr1 inhibits arterial neointimal hyperplasia in short term, but promotes an undesired vascular phenotype for injured arteries.
TGFbetaR1 signalling is needed for development of CD103 (Montrer ITGAE Anticorps)(+)CD11b (Montrer ITGAM Anticorps)(+) intestinal DCs from CD103 (Montrer ITGAE Anticorps)(-)CD11b (Montrer ITGAM Anticorps)(+) cells and that they contribute to the generation of Th17 and regulatory T cells.
Overactivation of TGFBR1 drives gonadal tumor development. The TGFBR1 constitutively active mouse model phenocopies a number of morphological, hormonal, and molecular features of human granulosa cell tumors and are potentially valuable for preclinical testing of targeted therapies to treat granulosa cell tumors, a class of poorly defined ovarian malignancies.
results indicate that CD34 (Montrer CD34 Anticorps)+ cells and signaling through ALK5 play pivotal roles in the morphogenesis of interstitial-like, peritubular-like and cord-like structures
a novel role for SREBP-1 (Montrer SREBF1 Anticorps) as a cell surface retention factor for TbetaRI in mesangial cells, is reported.
a surface population of Hsp90 (Montrer HSP90 Anticorps) extracellularly binds TGFbetaRI and this complex behaves as an active participant in collagen production in TGFbeta (Montrer TGFB1 Anticorps)-activated fibroblasts.
The protein encoded by this gene forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm. The encoded protein is a serine/threonine protein kinase. Mutations in this gene have been associated with Loeys-Dietz aortic aneurysm syndrome (LDAS). Multiple transcript variants encoding different isoforms have been found for this gene.
TGF-beta receptor type I
, TGF-beta receptor type-1
, TGF-beta type I receptor
, activin A receptor type II-like kinase, 53kD
, activin A receptor type II-like kinase, 53kDa
, activin A receptor type II-like protein kinase of 53kD
, activin receptor-like kinase 5
, serine/threonine-protein kinase receptor R4
, transforming growth factor beta receptor I
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD)
, transforming growth factor-beta receptor type I
, transforming growth factor, beta receptor 1 (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor beta type I receptor
, transforming growth factor, beta receptor 1
, transforming growth factor beta receptor 1
, activin A receptor type II-like kinase
, transforming growth factor beta receptor type I
, transforming growth factor beta, receptor 1
, type I serine/threonine kinase receptor
, TGF-beta receptor type-1-like
, transforming growth factor, beta receptor I